Dysregulation of the PI3K/Akt/mTOR pathway is one of the most frequent events in human cancer. However, the clinical benefits of PI3K/Akt/mTOR inhibitors have not yet achieved their predicted potential in many of the most prevalent human cancers. Of interest, treatment of Kaposi's sarcoma (KS) patients with rapamycin provided the first evidence of the antineoplastic activity of mTOR inhibitors in humans, becoming the standard of care for KS arising in renal transplant patients. Thus, the study of KS may provide a unique opportunity to dissect the contribution of specific mTOR downstream targets to cancer development. The KSassociated herpesvirus (KSHV) is the etiological agent for KS, and the KSHV-encoded oncogene viral-G protein-coupled receptor (vGPCR) promotes the potent activation of the PI3K-Akt-mTOR pathway by both direct and paracrine mechanisms. We focused on a direct target of mTOR, EIF4EBP1/2/3 (4EBP), which inhibits the translation of eukaryotic initiation factor 4E (eiF4E)-bound mRNAs. 4EBP phosphorylation by mTOR relieves its inhibitory activity, hence resulting in increased eiF4E-dependent mRNA translation. We developed a paracrine transformation model, recapitulating the cellular composition of KS lesions, in which vGPCR-expressing cells promote the rapid proliferation of endothelial cells, thus expressing KSHV-latent genes by the release of growth factors. Using this model, we show here that the accumulation of dephosphorylated 4EBP in response to rapamycin or by the expression of an mTORinsensitive mutant of 4EBP1 is sufficient to disrupt the eiF4E function downstream of mTOR to a similar extent than the mTOR catalytic inhibitor Torin2 and to halt KS development. We also provide evidence that eiF4E contributes to paracrine neoplastic, signaling through the release of pro-angiogenic factors that are acting on endothelial cells, expressing KSHV-latent genes. These findings may provide a preclinical platform and the rationale for the development of novel mTOR, inhibiting agents that may selectively disrupt the mTOR-4EBP interaction for the treatment of KS and other tumor lesions, exhibiting hyperactive mTOR pathway function.
INTRODUCTION
The mTOR signaling circuitry has a key role in a wide array of biological processes. 1 This serine-threonine kinase represents a point of convergence of growth factor receptors and multiple oncogenes that activate the PI3K-Akt pathway and, as such, dysregulation of mTOR represents one of the most frequent events in human cancer.
1,2 mTOR exists in two molecular complexes, the rapamycin sensitive mTOR complex 1 (mTORC1) and the insensitive mTOR complex 2, each one with specific roles and targets.
1 mTORC1 is positively regulated by growth signals and nutrients, with two extensively studied downstream effectors, p70 S6 kinase (p70 S6K , RPS6K1/2) and the EIF4EBP1/2/3 family (4EBP). RPS6K phosphorylates ribosomal protein S6, leading to increased ribosomal biogenesis and overall increase in protein translation, 3 whereas the phosphorylation of 4EBP prevents its interaction with the eiF4E, enabling its participation in the formation of the initiation complex eiF4F and the translation of 7mGTP-cap containing mRNAs. 4 Rapamycin and its analogs (rapalogs) are allosteric inhibitors of mTORC1 widely used in the clinic. Although recently approved for the treatment of advanced renal cell carcinoma, 5 targeting the mTOR pathway has not yet achieved its expected clinical activity in some cancers, displaying mTOR overactivity. 6 A notable exception is the activity of mTOR inhibitors in Kaposi's sarcoma (KS) patients. 7 This aggressive vascular tumor develops in immunocompromised patients including AIDS and organ transplant recipients as a result of the opportunistic infection or reactivation of the KS-associated herpesvirus (KSHV, also termed HHV-8), which induces atypical vascular proliferation in the skin and viscera. 8 Molecular dissection of the oncogenic drivers in KS unveiled the potent activation of the PI3K-Akt-mTOR pathway downstream of a KSHV-encoded oncogene, v-G protein-coupled receptor (vGPCR), 9 in endothelial cells. Treatment of patients developing KS in immunosuppressed renal transplanted patients provided the first evidence of the antineoplastic activity of mTOR inhibitors in humans, 10, 11 and is now the standard of care for this group of KS patients. Thus, the study of this rare neoplasia may provide a unique opportunity to dissect the specific contribution of mTOR downstream effectors. By the use of a paracrine transformation model and the expression of an Figure 1 . Antitumor properties of Rapamycin in experimental KS. (a) SV40-immortalized murine endothelial cells (SVEC4-10) were purchased from ATCC (Manassas, VA, USA). SVEC cells were cultured in DMEM 10% fetal bovine serum supplemented with antibiotics, 5% CO2 at 37 1C. SVEC vGPCR cells were generated by infection with an elongation factor 1 alpha (EF-1a)-driven N-terminal HA-tagged vGPCR-expressing lentiviral vector and selected by fluorimeter-activated cell sorting (FACS) against the HA epitope. SVEC vGPCR cells were starved overnight and treated with increasing concentrations of rapamycin, as indicated, for 1 h and lysed. A representative WB (procedure described in 17 ) shows a dose-dependent reduction in pS6 (rabbit polyclonal; Cell Signaling, Danvers, MA, USA) expression that is already evident at doses as low as 2 nM and almost complete 5-10 nM. Non-phosphorylated 4EBP T46 (rabbit polyclonal; Cell Signaling) also accumulates in a dose-dependent fashion. Control, parental cell line SVEC. (b). SVEC cells lines were used to induce endothelial tumor xenografts in athymic mice as described previously. 9 One million SVEC vGPCR or SVEC cells were injected into both flanks of female athymic (nu/nu) nude mice (Harlan SpragueDawley, Frederick, MD, USA), 5-6 weeks of age and weighing 18-20 g (n ¼ 16 tumors). Tumors were allowed to develop to a mean weight of B100 mg and then treated with Rapamycin (LC Laboratories, Woburn, MA, USA; 5 mg/kg, daily i.p.) or vehicle until the end of the study. Tumor mass was determined from tumor volume ((LW 2 /2); where L and W represent the length and the width of the tumor) by conversion to weight (mg) assuming unit density. Data points represent mean tumor mass for each group ± s.e.m. Rapamycin effectively inhibited tumor growth, with significant differences seen already at day 7 after treatment initiation. (c) Animals from the SVEC vGPCR control and rapamycin treatment groups were killed after 48 h of the beginning of the rapamycin treatment. Animals were injected with BrdU (5 mg/kg i.p.) 2 hours prior to euthanasia to label proliferating cells. Paraffin sections of the tumors were reacted as described previously 27 with antibodies against the mTOR activity marker pS6 (used 1:100) and the proliferation marker BrdU The mTOR/4EBP axis regulates Kaposi's sarcoma paracrine transformation D Martin et al mTOR-insensitive mutant of 4EBP1, we show here that the accumulation of dephosphorylated 4EBP in response to rapamycin is sufficient to disrupt the eiF4E function downstream of mTOR, and to halt KS development. We also provide evidence that eiF4E contributes to paracrine neoplastic signaling through the release of pro-angiogenic factors, acting on endothelial cells expressing KSHV-latent genes.
RESULTS AND DISCUSSION
The KSHV vGPCR oncogene encodes a constitutively active GPCR that is expressed during the lytic viral activation or aberrantly expressed in cells that fail to undergo a lytic cycle. 12 vGPCR induces chemokine, cytokine and growth factor secretion, thereby promoting the growth of other naive and latently infected endothelial cells in a paracrine fashion, 13 thus giving raise to the characteristic angioproliferative lesions of the KS. Although inefficient intratumoral vascular networks in cancer may limit the appropriate delivery of therapeutic agents, 14 the direct exposure of endothelial-derived KS cells to the bloodstream circumvents these limitations, thus creating an excellent scenario for the study of therapeutic molecular mechanisms. Rapamycin induced a marked decrease in the phosphorylation of the downstream target S6, as well as an accumulation of non- T46 at doses as low as 2 nM, with almost complete inhibition between 5 and 10 nM (Figure 1a ), which are the trough blood levels aimed for in KS treatment. 10 Rapamycin effectively halted the growth of SVEC vGPCR xenografts ( Figure 1b ) concomitant with a dramatic decrease in phospho-S6 (pS6) staining and cell proliferation as depicted by Bromodeoxyuridine (BrdU) incorporation, as we have previously reported 15 ( Figures 1c and d) , and an increase in apoptosis as detected by caspase 3 activation (Supplementary Figure S1) . Rapamycin also decreased the amount of phospho-4EBP (p4EBP), one of the mTORC1 targets, albeit incompletely as previously reported in other cancer models. 16 However, under these conditions, we observed a substantial accumulation of non-phosphorylated 4EBP (Figure 1e ), thus raising the possibility that 4EBP may still represent a biologically relevant target in KS.
KS tumoral mechanisms involve the paracrine induction of cell proliferation. 9 Several models have documented the contribution of a small number of vGPCR-expressing endothelial cells to the proliferation of adjacent endothelial cells, expressing other KSHV viral genes. 9, 17, 18 Here, we developed a simple paracrine transformation reporter system by engineering endothelial cells, expressing the three major KSHV-latent transcripts, vCyclin, vFlip and LANA, which we named SVEC KS-LT. The expression of these latent transcripts was confirmed by western blot and immunofluorescence (Figures 2a and b, and Supplementary Figure S2 ) against the corresponding epitopes for the tagged vCyclin and vFlip, and for the protein product for LANA. Despite the expression of these potentially transforming genes, basal cell proliferation was not altered when compared with control parental cells. However, vGPCR-expressing cells displayed a twofold increase in basal proliferation (Figure 2c) . Interestingly, when exposed to SVEC vGPCR-conditioned media, both parental control and SVEC KS-LT cells showed increased proliferation, the latter to a much greater extent (Figure 2d ). This hypersensitivity to vGPCR-induced secretions was further depicted by the robust induction of proliferation by increasing concentrations of vGPCRconditioned media. We challenged this paracrine-induced proliferation model in a mouse xenograft system. SVEC KS-LT cells failed to induce tumor growth when combined with a defined proportion (10%) of SVEC cells (Figure 2f) . Conversely, when mixed with 10% of SVEC vGPCR cells, mimicking the proportion of vGPCR-expressing cells present in human KS lesions, 13 tumors were formed, where most of the cells expressed the latent transcript LANA, closely resembling the abundance of LANA the most common diagnostic marker for KSHV infection in human KS (Figure 2g ). These results support the relevance of a paracrine neoplasia mechanism in KS, defining two distinct promoting and proliferating cellular compartments, cooperating in the formation of the KS lesion.
We next explored the contribution of mTOR to paracrine neoplasia, with a focus on 4EBP, as the ineffective inhibition of phosphorylation of 4EBP has been often associated with therapeutic failure of rapamycin. 19 We engineered a 4EBP mutant protein, where the residues T37, T46, S65 and T70 were mutated to alanine (4EBP-M). This mutant lacks the ability to be regulated by mTOR, and hence it is expected to mimic the disruption of the mTORC1 complex function by rapamycin on the downstream regulation of eiF4E function. Indeed, 7mGTP pulldown experiments (scheme in Figure 3a ) revealed that expression of 4EBP-M in SVEC vGPCR and SVEC RheB, both of which have elevated mTOR activity, prevented the association of eiF4E and eiF4G, effectively disrupting the formation of the translationinitiating eiF4F complex, to a degree similar to that induced by rapamycin or the mTOR catalytic inhibitor Torin2 20 ( Figure 3a) . Although the expression of 4EBP-M completely blocked eiF4E/ eiF4G association and reduced 4EBP phosphorylation, it only moderately affected S6 phosphorylation in SVEC vGPCR and SVEC RheB cells (Figure 3b) . Moreover, expression of 4EBP-M dramatically reduced the proliferation of both SVEC vGPCR and SVEC RheB cells in vitro (Figure 3c ) and their tumorigenic potential and proliferation rate in vivo (Figures 3d and e) , suggesting that the Figure 2 . Characterization of a cell line expressing the KSHV three major latent transcripts. (a) SVEC cells were stably transfected (ExGen 500, Fermentas, Hanover, MD, USA) with a naturally occurring bicistronic 28 DNA encoding an N-terminal AU5-tagged vCyclin and C-terminal HAtagged viral FLICE (FADD (Fas-associated death domain)-like IL1 beta-converting enzyme)-inhibitory protein (vFlip) proteins. 9 These cells where further infected with a lentivirus encoding the KSHV ORF 73 (LANA) under the control of the elongation factor 1 alpha (EF-1a) promoter and denominated SVEC KS-LT. As a control, cell lysates from 293T transiently transfected with the bicistronic, as well as LANA encoding vectors was used. Expression of the different proteins in pooled cultures was confirmed by western blot. Mouse monoclonal anti-HA (clone 12CA5) and anti-AU5 (clone MMS-135R) were used and purchased from Covance Research Products, Denver, PA, USA. Rat monoclonal anti-ORF73 (KSHV LANA) was purchased from Advanced Biotechnologies (Columbia, MD, USA). (b) Immunocytochemistry depicting the expression and localization of the latent transcripts in SVEC KS-LT. Briefly, cells were plated onto poly-D lysine-coated coverslips for 24 h washed once with cold PBS and fixed in 4% paraformaldehyde in PBS for 10 min at room temperature (RT). Cells were washed three times with PBS and permeabilized for 5 min with PBS containing 0.5% NP-40. Cells were washed again twice and incubated in blocking solution (3% BSA in PBS) for 20 min. Slides were incubated with the primary antibodies as indicated diluted 1:500 in blocking solution for 1 h at RT. After this incubation, the coverslips were washed with PBS and incubated with the appropriate Alexa546-conjugated secondary antibodies supplemented with Phalloidin-Alexa488 (Invitrogen, Carslbad, CA, USA) in blocking solution for 1 h at RT. Cells were then washed with PBS and nuclei stained with 1 mg/ml TO-PRO3, washed with PBS and distilled water, and mounted using FluorSafe mounting medium (EMD, Gibbstown, NJ, USA). Imaging was performed on a Zeiss LSM 700 confocal microscope. Bar ¼ 10 mm. (c) Cells were cultured in standard conditions at subconfluency, serum starved overnight, and cell proliferation was determined by EdU incorporation assay. Briefly, cells cultured in poly-D-lysine-treated coverslips, starved as indicated above and treated for 20 h. Then 10 mM EdU (Click-it kit, Invitrogen) was added to the cultures for 4 h and fixed in 4% paraformaldehide (Electron Microscopy Sciences, Fort Washington, PA, USA) in PBS. Nuclei where counterstained using Hoechst 33342 (Invitrogen) and visualized on an Axio Imager Z1 microscope equipped with ApoTome system controlled by the AxioVision software (Carl Zeiss, Thornwood, NY, USA). Fields were visually scored for the proportion of EdU positive nuclei (nX300) with respect to the total number of cells as determined by nuclear 4' ,6-diamidino-2-phenylindole (DAPI) staining. Bars represent the average proportions ± s.e.m. with respect to SVEC (Control) cells, ***Pp0.001. (Figures 4a and b) . In this regard, VEGF-A is a potent endothelial specific growth factor that contributes to KS development, and the VEGF expression levels are reduced by rapamycin Figure 3 . A dominant-positive 4EBP mutant prevents eiF4E-mediated vascular endothelial growth factor (VEGF) translation and tumorigenesis. (a) Left panel, scheme of the 7mGTP pull down depicting the regulation of complex formation by mTOR and 4EBP. Briefly, cells were starved and treated as described above, were quickly washed in ice-cold PBS and lysed in pull-down buffer (1 ml of 50 mM HEPES; pH 7.5), 150 mM NaCl, 10% glycerol, 0.3% (w/v) CHAPS, 1.5 mM MgCl 2 , 1 mM EGTA, 100 mM NaF, 500 mM sodium orthovanadate, 10 mg/ml aprotinin and 10 mg/ml leupeptin and 1 mM PMSF) and incubated at 4 1C for 2 h with 7mGTP-Sepharose beads (Amersham, Piscataway, NJ, USA). Beads were then washed three times with pull-down buffer and resuspended in Laemmli sample buffer and resolved by SDS-PAGE. Right panel, SVEC vGPCR and SVEC RheB cells were infected with lentiviral vectors encoding a 4EBP1 (T36A, T45A, S65A, T70A) mutant protein (4EBP-M). A representative 7mGTP pull-down experiment is shown depicting the prevention of eiF4G association to eiF4E by the expression of 4EBP-M, Rapamycin and Torin2. (b) Exponentially growing cell cultures were starved as indicated in the experimental procedures and then treated with 100 nM rapamycin for 1 h and lysed. The panel shows a representative western blot analysis of SVEC vGPCR and SVEC RheB cells, in which the expression of 4EBP-M completely blocked eiF4E/eiF4G association and reduced 4EBP phosphorylation. S6 phosphorylation was not significantly affected. (Figure 3b The mTOR/4EBP axis regulates Kaposi's sarcoma paracrine transformation D Martin et al treatment. 21, 22 Inhibition of eiF4E by 4EBP-M was concomitant with a decrease secretion of VEGF-A in the conditioned media (Figure 4c) , even in the absence of a significant alteration in the levels of VEGF-A mRNA (Figure 4d ), compatible with a decrease in translation of VEGF-A mRNA. In addition, the secretion of two potent angiogenic cytokines involved in KS, interleukin (IL) 6 and KC/Cxcl1, the latter the murine homolog of IL8/Gro-a, were both also reduced by 4EBP-M expression (Figures 4e and f, respectively) . The biological impact of 4EBP-M in paracrine signaling was reflected in the xenograft model in vivo, where 4EBP-M expression (Figure 4g ) and a dramatic impairment of tumor growth (Figure 4f ). The molecular mechanism whereby rapamycin exerts its antitumoral effects remains unclear, given the emerging complexity of the mTOR network.
1 In our experimental model, rapamycin treatment induced tumor regression concomitant with a dramatic decrease in pS6, which has served as a prototypical mTOR activity marker, but only a moderate decrease in p4EBP was achieved. The perceived resistance of 4EBP to complete dephosphorylation upon rapamycin treatment in this and other systems has prompted the denomination of rapalogs as incomplete mTOR inhibitors, 19 thereby prompting the development of a novel class of mTOR catalytic inhibitors in the last few years. 20 Interestingly, however, the availability of commercial antibodies detecting the non-phosphorylated 4EBP, revealed the accumulation of the dephosphorylated form of this protein in vitro and in vivo after rapamycin treatment. Moreover, rapamycin was able to disrupt the interaction of eiF4G and eiF4E to a similar degree than that achieved by the potent second generation mTOR catalytic inhibitor Torin2. 20 This in turn suggests that despite the presence of considerable amounts of p4EBP remaining after rapamycin treatment, the accumulation of small quantities of nonphosphorylated 4EBP, which possesses a very high affinity in this state for eiF4E, 23 might be enough to effectively prevent eiF4E and eiF4G interaction and block cap-dependent protein translation to an extent sufficient to inhibit KS sarcomagenesis.
Although our studies support a central role for the 4EBP branch downstream of mTOR in KSHV vGPCR-induced sarcomagenesis, these findings do not exclude the necessity of the concomitant activation of S6 kinase by mTOR, a possibility that warrants further investigation. Of interest, 4EBP is often overexpressed in a variety of tumors that concomitantly display elevated mTOR activity, including ovarian, kidney, brain, cervical, prostate, and head and neck cancers (source: Oncomine). This suggests that cells undergoing mTOR-driven transformation could upregulate 4EBP expression as means to slow down or even prevent tumor progression, but ultimately failing to do so when the 4EBP-eiF4E interaction is disrupted by its persistent phosphorylation by mTOR. However, this process may result an still unexploited tumor vulnerability, as even incomplete mTOR inhibition would result in the accumulation of enough non-phosphorylated 4EBP to quench eiF4E effectively, thereby halting tumor growth. 23 This possibility was further supported by the use of genetic approaches to specifically disrupt eiF4E function by the use of an unphosphorylatable 4EBP mutant, which blocked the formation of the initiation complex eiF4F and prevented tumor growth by vGPCR and RheB, the latter acting directly upstream of mTOR.
The precise transforming genes whose translation is regulated by mTOR in KS warrant further investigation. In this regard, while several secreted cytokines and growth factors are known to have a role in KS, the roles of VEGF-A, IL8 and IL6 are the best studied. 24, 25 Owing to the paracrine nature of KSHV-induced transformation, 26 cells expressing the three major latent KSHV genes, LANA, vFLIP and vCyclin, fail to induce cellular transformation on their own but proliferate readily in response to vGPCR-induced growth factors, including VEGF-A. Overall, our results suggest that the accumulation of the under phosphorylated form of 4EBP may limit the eiF4E-dependent translation of mRNAs required for vGPCR-induced cell proliferation, as well as the secretion of chemokines, cytokines and growth factors that contribute to the proliferation of latently infected cells in a paracrine fashion (Figure 4g ). Indeed, we now provide evidence that by limiting protein translation by interfering with the mTOR/4EBP axis is sufficient to disrupt the intercellular paracrine communication, resulting in KS sarcomagenesis. In turn, these findings may provide a preclinical platform and the rationale for the development of novel mTOR inhibiting agents that may selectively disrupt the mTOR-4EBP interaction for the treatment of KS, as well as other tumor lesions, exhibiting hyperactive mTOR pathway function.
